Oral insulin composition and methods of making and using thereof
First Claim
Patent Images
1. A method of lowering blood glucose in a mammal, comprising orally administering a therapeutically effective amount of a composition comprising crystallized dextran microparticles and insulin to the mammal to lower blood glucose of the mammal.
1 Assignment
0 Petitions
Accused Products
Abstract
A method of lowering blood glucose in a mammal includes orally administering a therapeutically effective amount of crystallized dextran microparticles and insulin to the mammal to lower blood glucose of the mammal. The composition may be a one phase or a structured multi-phase composition for controlled release of insulin.
61 Citations
40 Claims
- 1. A method of lowering blood glucose in a mammal, comprising orally administering a therapeutically effective amount of a composition comprising crystallized dextran microparticles and insulin to the mammal to lower blood glucose of the mammal.
- 13. A method of lowering blood glucose in a mammal, comprising orally administering a composition comprising a therapeutically effective amount of insulin and a matrix material to the mammal to lower blood glucose of the mammal by at least 5 percent 60 minutes after administering the suspension to the mammal.
-
25. A method of administering a suspension to a mammal, comprising orally administering an aqueous suspension of crystallized dextran microparticles and a therapeutically effective amount of insulin to the mammal.
- 26. A dosed pharmaceutical composition, comprising crystallized dextran microparticles and a therapeutically effective amount of insulin, wherein the composition is dosed for oral administration to a human.
-
34. A pharmaceutical composition kit, comprising:
-
an aqueous suspension of crystallized dextran microparticles and a therapeutically effective amount of insulin located in a vessel; and
instructions for oral administration of the composition to a human in need thereof.
-
-
35. A pharmaceutical kit, comprising:
-
a first means for orally administering to a mammal to lower blood glucose of the mammal by at least 30 percent 60 minutes after administering the suspension to the mammal; and
a storage vessel containing the first means.
-
-
36. A tablet comprising a pharmaceutically acceptable carrier medium, crystallized dextran microparticles and a therapeutically effective amount of insulin.
-
37. A capsule comprising a pharmaceutically acceptable shell, crystallized dextran microparticles and a therapeutically effective amount of insulin.
-
38. A method of making a dosed pharmaceutical composition, comprising:
-
providing crystallized dextran microparticles;
combining a therapeutically effective amount of insulin and the crystallized dextran microparticles in a solution after the microparticles have been crystallized to form a composition of insulin and crystallized dextran microparticles; and
dosing the composition for oral administration to a mammal. - View Dependent Claims (39, 40)
-
Specification